Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure

Bibliography

• Cardiovascular Diseases Factsheet #317. In: World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html [Accessed 24 September 2012]
   Google Scholar
• European Cardiovascular Disease Statistics 2008. In: European Heart Network. Available from: http://www.ehnheart.org/cvd-statistics.html [Accessed 24 September 2012]
   Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, Heart disease and stroke statistics—2012 update. A report from the American Heart Association. Circulation 2012;125:e2-e220
   PubMed Web of Science ®Google Scholar
• Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17-23
   PubMed Web of Science ®Google Scholar
• Yang J, Goetz D, Li JY. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10(5):1045-56
   PubMed Web of Science ®Google Scholar
• Mori K, Leet HT, Rapoport D, Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-21
   PubMed Web of Science ®Google Scholar
• Elneihoum AM, Falke P, Hedblad B, Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84
   PubMed Web of Science ®Google Scholar
• Zografos T, Haliassos A, Korovesis S, Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009;104:917-20
   PubMed Web of Science ®Google Scholar
• Hemdahl AL, Gabrielsen A, Zhu C, Expression of neutrophil gelatinase–associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136-42
   PubMed Web of Science ®Google Scholar
• Lindberg S, Pedersen SH, Mogelvang R, Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2012;60:339-45
   PubMed Web of Science ®Google Scholar
• Sahinarslan A, Kocaman SA, Bas D, Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron Artery Dis 2011;22:333-8
   PubMed Web of Science ®Google Scholar
• Mishra J, Mori K, Ma Q. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-82
   PubMed Web of Science ®Google Scholar
• Mishra J, Ma Q, Prada A, Identification of NGAL as a novel early urinary marker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43
   PubMed Web of Science ®Google Scholar
• Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32
   PubMed Web of Science ®Google Scholar
• Miethke M, Skerra A. Neutrophil gelatinase-associated lipocalin expresses antimicrobial activity by interfering with L-norepinephrine-mediated bacterial acquisition. Antimicrob Agents Chemother 2010;54:1580-9
   PubMed Web of Science ®Google Scholar
• Flower DR. The lipocalin protein family: structure and function. Biochem J 1996;318:1-14
   PubMed Web of Science ®Google Scholar
• Zappitelli M, Washburn KK, Arikan AA, Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007;11:R84
   PubMed Web of Science ®Google Scholar
• Mishra J, Dent C, Tarabishi R. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 1998;356:1231-8
   Google Scholar
• Makris K, Markou N, Evodia E. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009;47:79-82
   PubMed Web of Science ®Google Scholar
• de Geus HR, Bakker J, Lesaffre EM, le Noble JL. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 2011;183:907-14
   PubMed Web of Science ®Google Scholar
• Bolignano D, Lacquaniti A, Coppolino G, Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337-44
   PubMed Web of Science ®Google Scholar
• Mitsnefes M, Kathman T, Mishra J. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007;22:101-8
   PubMed Web of Science ®Google Scholar
• Bolignano D, Coppolino G, Campo S, Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008;23:414-16
   PubMed Web of Science ®Google Scholar
• Aghel A, Shrestha K, Mullens W, Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010;16:49-54
   PubMed Web of Science ®Google Scholar
• Alvelos M, Lourenco P, Dias C, Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Maisel AS, Mueller C, Fitzgerald RL, Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL evaluation along with B-type NaTriuretic peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13:846-51
   PubMed Web of Science ®Google Scholar
• Goetz DH, Willie ST, Armen RS, Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000;39:1935-41
   PubMed Web of Science ®Google Scholar
• Hannson GK, Hellstrand M, Rymo L, Interferon (IFN) Gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989;170:1595-608
   PubMed Web of Science ®Google Scholar
• Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-65
   PubMed Web of Science ®Google Scholar
• Yndestad A, Landrø Ueland T, Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur J Heart Fail 2009;30:1229-36
   Web of Science ®Google Scholar
• Kafkas T, Matthew J, Yang J, Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810-19
   PubMed Web of Science ®Google Scholar
• Freda BJ, Tang WH, Van Lente F, Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40(12):2065-71
   PubMed Web of Science ®Google Scholar
• Alvelos M, Pimental R, Pinho E, Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol 2011;6(3):476-81
   PubMed Web of Science ®Google Scholar
• Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 2011;31(2):72-80
   PubMed Web of Science ®Google Scholar
• Torregrosa I, Montoliu C, Urios A, Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Nefrologia 2012;32(1):44-52
   PubMed Web of Science ®Google Scholar
• Nishida M, Kawakatsu H, Okumura Y, Hamaoka K. Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases. Pediatr Int 2010;52:563-8
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol Dial Transplant 2007;22:295-6
   PubMed Web of Science ®Google Scholar
• Damman K, van Veldhuisen D, Navis G, Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008;10(10):997-1000
   PubMed Web of Science ®Google Scholar
• Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010;40(3):273-6
   PubMed Web of Science ®Google Scholar
• Daniels LB, Barrett-Connor E, Clopton P, Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: the Rancho Bernardo study. J Am Coll Cardiol 2012;59(12):1101-9
   PubMed Web of Science ®Google Scholar
• Smith C, Damas JK, Otterdal K, Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 2006;48:1591-9
   PubMed Web of Science ®Google Scholar
• Paulsson J, Dadfar E, Held C, Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 2007;192:328-34
   PubMed Web of Science ®Google Scholar
• Elneihoum AM, Falke P, Axelsson L, Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996;27:1734-8
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, NGAL (neutrophil gelatinaseassociatedlipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol 2008;127:290-1
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 2009;54(2):221-4
   PubMed Web of Science ®Google Scholar
• Nymo SH, Ueland T, Askevold CT, The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 2012;271(5):436-43
   PubMed Web of Science ®Google Scholar
• Shrestha K, Borowski AG, Troughton RW, Renal Dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011;17(6):472-8
   PubMed Web of Science ®Google Scholar
• Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999;111(5):406-16
   PubMedGoogle Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Adams K Jr, State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10(9):824-39
   PubMed Web of Science ®Google Scholar
• Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91(5):606-12
   PubMed Web of Science ®Google Scholar
• Clerico A, Fontana M, Zyw L, Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53(5):813-22
   PubMed Web of Science ®Google Scholar
• Januzzi JL, van Kimmenade R, Lainchbury J, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27(3):330-7
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007;297(2):169-76
   PubMed Web of Science ®Google Scholar
• Moertl D, Berger R, Struck J, Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009;53(19):1783-90
   PubMed Web of Science ®Google Scholar
• Potocki M, Breidthardt T, Reichlin T, Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010;267(1):119-29
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55(19):2062-76
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Jankowska EA, Morgenthaler NG, Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50(20):1973-80
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Alonso C, Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51(10):1823-9
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak RM, Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011;58(10):1057-67
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, Hurwitz S, Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Januzzi JL Jr. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010;10(4):459-64
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Peacock W, Maisel AS, Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50(7):607-13
   PubMed Web of Science ®Google Scholar
• Kehl DW, Iqbal N, Fard A, Biomarkers in acute myocardial injury. Transl Res 2012;159(4):252-64
   PubMed Web of Science ®Google Scholar
• de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7(1):1-8
   PubMedGoogle Scholar
• McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12(4):200-10
   PubMed Web of Science ®Google Scholar
• Grandin EW, Jarolim P, Murphy SA, Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58(1):267-73
   PubMed Web of Science ®Google Scholar
• de Boer RA, Lok DJ, Jaarsma T, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43(1):60-8
   PubMed Web of Science ®Google Scholar
• Morrow DA, Cannon CP, Jesse RL, National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115(13):e356-75
   PubMedGoogle Scholar
• Thygesen K, Mair J, Giannitsis E, the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33(18):2252-7
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Bamberg F, Lee H, High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121(10):1227-34
   PubMed Web of Science ®Google Scholar
• Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med Clin North Am 2007;91:657-81
   PubMed Web of Science ®Google Scholar
• Lin JC, Apple FS, Murakami MM, Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem 2004;50(2):333-8
   PubMed Web of Science ®Google Scholar
• Stec JJ, Silbershatz H, Tofler GH, Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102(14):1634-8
   PubMed Web of Science ®Google Scholar
• Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem 2010;56(5):693-5
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258(9):1183-6
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007;99(5):718-25
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12
   PubMed Web of Science ®Google Scholar
• Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005;105(9):409-16
   PubMedGoogle Scholar
• Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116(16):1832-44
   PubMed Web of Science ®Google Scholar
• Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007;27(3):661-70
   PubMed Web of Science ®Google Scholar
• Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011;58(5):457-63
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Barringer TA. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009;11(6):468-75
   PubMedGoogle Scholar
• Duriez P, Dallongeville J, Fruchart JC. Lipoprotein (a) as a marker for coronary heart disease. Br J Clin Pract Suppl 1994;77):51-8
   PubMedGoogle Scholar
• Nordestgaard BG, Chapman MJ, Ray K, European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53
   PubMed Web of Science ®Google Scholar
• Bostom AG, Cupples LA, Jenner JL, Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276(7):544-8
   PubMed Web of Science ®Google Scholar
• Luc G, Bard JM, Arveiler D, PRIME Study Group. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163(2):377-84
   PubMed Web of Science ®Google Scholar
• Bolignano D, Coppolino G, Lacquaniti A, Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008;31:274-9
   PubMed Web of Science ®Google Scholar
• Bolignano D, Donato V, Coppolino G, Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605
   PubMed Web of Science ®Google Scholar
• Elneihoum AM, Falke P, Hedblad B, Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84
   PubMed Web of Science ®Google Scholar
• Alvelos M, Lourenco P, Dias C, Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bu DX, Hemdahl AL, Gabrielsen A, Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006;169:2245-53
   PubMed Web of Science ®Google Scholar
• Devarajan P. Neutrophil gelatinase-associated liopcalin: a promising biomarker for human acture kidney injury. Biomark Med 2010;4:265-80
   PubMed Web of Science ®Google Scholar